In mice engrafted with glioblastoma stem cells (GSCs), MA2 treatment significantly reduced tumour size, and prolonged survival, suggesting the therapeutic potential of increasing m6A level through FTO inhibition.174. The gene discussed is FTO; the disease is neoplasm.